Moreover, the combination of PX-478 with the ferroptosis-inducing agent SAS had a synergistic anticancer effect in both in vitro and in vivo models, suggesting a potential therapeutic strategy for sensitizing glioma cells to ferroptosis through targeting the PI3K/AKT/HIF-1α/SLC7A11 axis. This evidence concerns the gene AKT1 and glioma.